A Correlation of FTIR Spectra Derived from Prostate Cancer Biopsies with Gleason Grade and Tumour Stage

European Urology

Volumn 50, Issue 4, 2006, Pages 750-761

  Gazi, Ehsan ^a,b   Baker, Matthew ^a   Dwyer, John ^a   Lockyer, Nicholas P ^a   Gardner, Peter ^a   Shanks, Jonathan H ^c   Reeve, Roy S ^d   Hart, Claire A ^b   Clarke, Noel W ^b,d   Brown, Michael D ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d HOPE HOSPITAL   (United Kingdom)

Author keywords

FTIR microspectroscopy; Gleason grade; Molecular diagnosis; Multivariate analysis; Prostate cancer; Tumour stage

Indexed keywords

ARTICLE; CANCER STAGING; CORRELATION ANALYSIS; DISCRIMINANT ANALYSIS; GLEASON SCORE; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; INFRARED SPECTROSCOPY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; TUMOR BIOPSY;

BIOPSY; FOURIER ANALYSIS; HUMANS; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 33748286685     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.03.031     Document Type: Article

References (21)

1. Gleason D.F. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M. (Ed). Urological pathology-the prostate (1977), Lee & Febiger, Philadelphia, PA 171-197
2. Tetu B. Morphologic changes induced by neoadjuvant combination hormone therapy on prostatic tissue and prostate cancer. Endocr Relat Cancer 3 (1996) 165-170
3. Lattouf J.B., and Saad F. Gleason score on biopsy: is it reliable for predicting the final grade on pathology?. BJU Int 90 (2002) 694-699
4. Smith E.B., Frierson H.F., Millis S.E., Boyd J.C., and Teodorscu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years. Is there evidence of systemic upgrading?. Cancer 94 (2002) 2282-2287
5. Epstein J.I., Pizov G., and Walsh P.C. Correlation of pathological findings with progression after radical retropubic prostatectomy. Cancer 71 (1993) 3582-3593
6. Levin I.W., and Bhargava R. Fourier transform infrared vibrational spectroscopic imaging: integrating microscopy and molecular recognition. Annu Rev Phys Chem 56 (2005) 429-474
7. Crow P., Stone N., Kendall C.A., et al. The use of Raman spectroscopy to identify and grade prostatic adenocarcinoma in vitro. Br J Cancer 89 (2003) 106-108
8. Malins D.C., Johnson P.M., Wheeler T.M., Barker E.A., Polissar N.L., and Wheeler T.M. Cancer-related changes in prostate DNA as men age and early identification of metastases in primary prostate tumours. Proc Natl Acad Sci USA 100 (2003) 5401-5406
9. Bertucci F., Viens P., Tagett R., Nguyen C., Houlgatte R., and Birnbaum D. DNA arrays in clinical oncology: promises and challenges (minireview). Lab Invest 83 (2003) 305-316
10. Gazi E., Dwyer J., Gardner P., et al. Applications of FTIR-microspectroscopy to benign prostate and prostate cancer. J Pathol 201 (2003) 99-108
11. Gazi E., Dwyer J., Lockyer N.P., et al. The combined application of FTIR microspectroscopy and ToF-SIMS imaging in the study of prostate cancer. Faraday Discuss 126 (2004) 41-59
12. Fernandez D.C., Bhargava R., Hewitt S.M., and Levin I.W. Infrared spectroscopic imaging for histopathologic recognition. Nat Biotechnol 23 (2005) 469-474
13. Stuart B. Instrumentation. Biological applications of infrared spectroscopy (1997), John Wiley & Sons, London, United Kingdom 26 p
14. Discriminant function analysis. In: Tabachnick, B.G., Fidell, L.S., editors. Using multivariate statistics, ed. 4. London, United Kingdom: Pearson; 2001. p. 456-61.
15. Zagars G.K., Pollack A., and vonEschenbach A.C. Prognostic factors for clinically localized prostate carcinoma-analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 79 (1997) 1370-1380
16. Coetzee L.J., Layfield L.J., Hars V., and Paulson D.F. Proliferative index determination in prostatic carcinoma tissue: is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage?. J Urol 157 (1997) 214-218
17. Benaim E.A., Pace C.M., and Roehrborn C.G. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urol 42 (2002) 12-17
18. Lapointe J., Li C., Higgins J.P., et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101 (2004) 811-816
19. Osterling J.E., Brendler C.B., Epstein J.I., Kimball A.W., and Walsh P.C. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathologic stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 138 (1987) 92-98
20. Gleason D.F. Histologic grading of prostate cancer: a perspective. Hum Pathol 23 (1992) 273-279
21. General discussion. Faraday Discuss 2004;126:77-92.